Road safety and breakdown organisation GEM Motoring Assist has produced a line-up of handy information to assist older p ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Romberg test was not performed before the intervention due to trunk instability; after treatment participants presented minimal balance changes ... peripheral nerves are relatively scarce, given that ...

Annexon's lead investigational therapy, tanruprubart, is a first-of-its kind selective, targeted and rapid-acting agent designed to reduce inflammation and nerve damage by stopping C1q activity in the ...

In GBS, tanruprubart is designed to seek out C1q and prevent its binding to targets on peripheral nerves. Tanruprubart is administered intravenously and has been observed to act almost immediately ...

at the 2025 Peripheral Nerve Society (PNS) Annual Meeting being held May 17-20, 2025 in Edinburgh, UK. GBS is a neuromuscular emergency and rare autoimmune disease that affects at least 150,000 ...

at the 2025 Peripheral Nerve Society (PNS) Annual Meeting being held May 17-20, 2025 in Edinburgh, UK. GBS is a neuromuscular emergency and rare autoimmune disease that affects at least 150,000 people ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI® remain progression-free CARTITUDE-4 analysis shows compelling overall survival and ...

In mid-February, parts of India witnessed a second spurt this year in cases of Guillane-Barré syndrome, a nerve ... change and Campylobacter, the bacteria linked with the current GBS outbreak ...